Özlem Türeci
Özlem Türeci
Unknown affiliation
Verified email at
Cited by
Cited by
Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
FP Polack, SJ Thomas, N Kitchin, J Absalon, A Gurtman, S Lockhart, ...
New England journal of medicine 383 (27), 2603-2615, 2020
Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
EE Walsh, RW Frenck Jr, AR Falsey, N Kitchin, J Absalon, A Gurtman, ...
New England Journal of Medicine 383 (25), 2439-2450, 2020
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
U Sahin, E Derhovanessian, M Miller, BP Kloke, P Simon, M Löwer, ...
Nature 547 (7662), 222-226, 2017
mRNA-based therapeutics—developing a new class of drugs
U Sahin, K Karikó, Ö Türeci
Nature reviews Drug discovery 13 (10), 759-780, 2014
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
U Sahin, A Muik, E Derhovanessian, I Vogler, LM Kranz, M Vormehr, ...
Nature 586 (7830), 594-599, 2020
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
MJ Mulligan, KE Lyke, N Kitchin, J Absalon, A Gurtman, S Lockhart, ...
Nature 586 (7830), 589-593, 2020
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
YT Chen, MJ Scanlan, U Sahin, Ö Türeci, AO Gure, S Tsang, ...
Proceedings of the National Academy of Sciences 94 (5), 1914-1918, 1997
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
LM Kranz, M Diken, H Haas, S Kreiter, C Loquai, KC Reuter, M Meng, ...
Nature 534 (7607), 396-401, 2016
Human neoplasms elicit multiple specific immune responses in the autologous host.
U Sahin, O Türeci, H Schmitt, B Cochlovius, T Johannes, R Schmits, ...
Proceedings of the national academy of sciences 92 (25), 11810-11813, 1995
Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
SJ Thomas, ED Moreira Jr, N Kitchin, J Absalon, A Gurtman, S Lockhart, ...
New England Journal of Medicine 385 (19), 1761-1773, 2021
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
S Kreiter, M Vormehr, N Van de Roemer, M Diken, M Löwer, J Diekmann, ...
Nature 520 (7549), 692-696, 2015
Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents
RW Frenck Jr, NP Klein, N Kitchin, A Gurtman, J Absalon, S Lockhart, ...
New England Journal of Medicine 385 (3), 239-250, 2021
Exploiting the mutanome for tumor vaccination
JC Castle, S Kreiter, J Diekmann, M Löwer, N Van de Roemer, J de Graaf, ...
Cancer research 72 (5), 1081-1091, 2012
Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices
T Sturniolo, E Bono, J Ding, L Raddrizzani, O Tuereci, U Sahin, ...
Nature biotechnology 17 (6), 555-561, 1999
Personalized vaccines for cancer immunotherapy
U Sahin, Ö Türeci
Science 359 (6382), 1355-1360, 2018
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells
S Holtkamp, S Kreiter, A Selmi, P Simon, M Koslowski, C Huber, ...
Blood 108 (13), 4009-4017, 2006
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
U Sahin, P Oehm, E Derhovanessian, RA Jabulowsky, M Vormehr, ...
Nature 585 (7823), 107-112, 2020
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
U Sahin, A Muik, I Vogler, E Derhovanessian, LM Kranz, M Vormehr, ...
Nature 595 (7868), 572-577, 2021
Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age
EB Walter, KR Talaat, C Sabharwal, A Gurtman, S Lockhart, GC Paulsen, ...
New England Journal of Medicine 386 (1), 35-46, 2022
Neutralization of SARS-CoV-2 lineage B. 1.1. 7 pseudovirus by BNT162b2 vaccine–elicited human sera
A Muik, AK Wallisch, B Sänger, KA Swanson, J Mühl, W Chen, H Cai, ...
Science 371 (6534), 1152-1153, 2021
The system can't perform the operation now. Try again later.
Articles 1–20